On March 30, 2026 Certis Oncology, an AI-enabled translational science company, reported the launch of Certis Oncology Intelligence, an integrated platform designed to generate data-driven insights into therapeutic response by combining predictive modeling, agentic AI-enabled biological data exploration, and functional validation in clinically relevant cancer models.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Certis Oncology Intelligence represents a new approach to translational research—one that connects computational prediction with real-world biological evidence in a continuous learning system.

Share
Certis Oncology Intelligence represents a new approach to translational research—one that connects computational prediction with real-world biological evidence in a continuous learning system.

"One of the central challenges in oncology drug development is that we generate enormous amounts of data, but struggle to translate that into reliable predictions of therapeutic response," said Peter Ellman, Certis President and CEO. "Certis Oncology Intelligence was built to close that gap—linking prediction, biological context, and experimental validation into a system that continuously learns and improves over time."

A Three-Layer Translational Intelligence System

Certis Oncology Intelligence is a secure, multi-tenant, closed loop system that integrates three data layers:

1.

Predictive Intelligence Layer— CertisAI

A patented, generalized drug-response foundation model trained to internalize relationships between chemical structure, tumor biology, and therapeutic response, CertisAI enables zero-shot prediction of how cancers are likely to respond to therapeutic agents, including novel compounds, even in the absence of prior experimental data.

This predictive layer can be fine-tuned using sponsor training data, producing powerful, custom computational models uniquely aware of each company’s novel chemical space.

2.

Exploration Layer — Agentic Biospecimen Management

Agentic biospecimen management enables researchers to dynamically query and analyze biological specimens together with their associated molecular and experimental datasets—offering a secure in silico environment in which to rapidly test hypotheses.

Within the Oncology Intelligence platform, licensors can integrate their own proprietary datasets—molecular profiles, drug-response screening results, target binding data, and other translational information accumulated across programs over many years.

By cross-referencing a company’s proprietary datasets with the platform’s foundational training data, the system can surface previously hidden relationships within each sponsor’s institutional knowledge base—generating new hypotheses, translational insights, and opportunities to advance or reprioritize therapeutic programs.

3.

Validation Layer—Functional Biological Evidence

A key differentiator of this platform is its ability to learn from continuous biological validation using experimental data generated either by Certis or by its collaborators. Validation data may include results from studies performed in human-concordant cancer models such as patient-derived xenografts (PDX), as well as in vitro assays, organoid models, or clinical trials.

Importantly, results from experimental studies are seamlessly fed back into the system as additional training data, continually improving predictive performance over time.

Unlocking the Value of Translational Data

The platform is designed to help pharmaceutical and biotechnology companies:

Integrate diverse datasets across programs and time
Identify biologically meaningful drivers of therapeutic response
Generate and test hypotheses more efficiently
Improve confidence in translational and clinical decision-making
By enabling organizations to extract new insights from existing data while continuously generating new evidence, Certis Oncology Intelligence offers a scalable foundation for more predictive and data-driven oncology development.

Availability

Certis Oncology Intelligence is available to pharmaceutical and biotechnology partners through licensing and collaborative engagements.

(Press release, Certis Oncology Solutions, MAR 30, 2026, View Source [SID1234664039])